Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
CDC42 SGC Tm panel (DSF)
Assay data:1 Tested
SummaryRelated BioAssays by Target
CDC42BPA SGC Tm panel (DSF)
Inhibition of Cdc42 in human HeLa cells by Flow cytometric G-trap effector binding assay
Assay data:1 Active, 1 Tested
Inhibition of Cdc42 GTPase in human breast cancer cell line treated for 24 hrs by western blot assay
Assay data:1 Active, 1 Activity ≤ 1 µM, 1 Tested
Inhibition of CDC42 delta (unknown origin) at 50 nM by Z'LYTE screening method relative to control
Assay data:12 Tested
SummaryPubMed CitationRelated BioAssays by Target
Inhibition of GST-tagged human intersectin-1 RhoGEF (1227 to 1571 residues) expressed in mouse NIH/3T3 cells assessed as reduction in human full length Cdc42 (1 to 191 residues) interaction with intersectin-1 RhoGEF at 50 to 200 uM incubated for 1 hr by Western blot analysis based pull-down assay
Inhibition of Cdc42 in human MDA-MB-231 cells assessed as inhibition of lamellipodia formation at 2 to 4 uM incubated for 24 hrs rhodamine phalloidin staining based fluorescence microscopy
Inhibition of Cdc42 in human MDA-MB-435 cells assessed as inhibition of lamellipodia formation at 2 to 4 uM incubated for 24 hrs rhodamine phalloidin staining based fluorescence microscopy
Inhibition of Cdc42 in human MDA-MB-435 cells assessed as remaining enzyme activity at 10 uM by Western blotting based pulldown assay (Rvb = 100%)
Inhibition of Cdc42 in human MDA-MB-435 cells assessed as remaining enzyme activity at 5 uM by Western blotting based pulldown assay (Rvb = 100%)
Inhibition of Cdc42 in human MDA-MB-435 cells assessed as remaining enzyme activity at 4 uM by Western blotting based pulldown assay (Rvb = 100%)
Inhibition of Cdc42 in human MDA-MB-435 cells assessed as remaining enzyme activity at 2 uM by Western blotting based pulldown assay (Rvb = 100%)
RNAi screen for vemurafenib enhancer genes in BRAFV600 melanoma - Primary Screen
Assay data:790 Active, 18119 Tested
Summary
Inhibition of RAC1/CDC42 in human ovarian cancer cells
Assay data:2 Active, 1 Activity ≤ 1 µM, 2 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Displacement of BODIPY-GTP from nucleotide binding site of GST-tagged activated Cdc42 GTPase (unknown origin) at 100 nL after 2 hrs by flow cytometry
Displacement of BODIPY-GTP from nucleotide binding site of wild-type GST-tagged Cdc42 GTPase (unknown origin) at 100 nL after 2 hrs by flow cytometry
Displacement of BODIPY-GTP from nucleotide binding site of GST-tagged activated Cdc42 GTPase (unknown origin) after 2 hrs by flow cytometry
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on